A tablet compression machine broke down mid-batch. The firm replaced it with a different make and model, continued manufacturing, and never revalidated cleaning or requalified the equipment. Eighteen months later, the FDA found it. The Dr. Reddy's FTO-SEZ 483 reveals what happens when equipment change control exists on paper but not in practice.
On December 12, 2025, FDA investigators issued a Form 483 to Dr. Reddy’s Laboratories Limited at their FTO-SEZ, Process Unit-01 facility in Devunipalavalasa Village, Ranasthalam Mandal, Srikakulam, Andhra Pradesh — a finished dosage manufacturing site producing multiple drug products for the US market. Three observations, each tracing back to a single event: a tablet compression machine that broke down on March 16, 2024.
The firm replaced the broken feeder (ID # PR034) with a different feeder of a different make and model (ID # PR182). Manufacturing continued. But as of December 12, 2025 — eighteen months after the swap — the firm had not revalidated the cleaning of the new equipment train, had not requalified the tablet compression machine with the replacement feeder, and could not even provide surface area calculations for the original feeder to verify whether the replacement was equivalent.
The cleaning validation for the equipment train had been conducted using a worst-case molecule, documented in Cleaning Validation Report VALRP-FS01-000310, effective October 6, 2020. That validation was built around the original equipment configuration. When the feeder changed — with a different make, different model, and according to the Head of Production, a larger surface area — the validated state ceased to exist. The firm continued manufacturing as though it had not. Following a step-by-step cleaning validation protocol that treats equipment changes as revalidation triggers would have caught the gap before the first affected batch.
Separately, the FDA found OOS dissolution results for two batches that were invalidated and released based on a hypothesis — paddle misplacement — that was never confirmed and was contradicted by the investigation’s own documentation.
The feeder broke down mid-batch. The replacement had a different make, different model, and a larger surface area. The firm never revalidated cleaning, never requalified the equipment, and continued manufacturing multiple US-market products on the unvalidated train for eighteen months. The FDA found it because the firm could not produce surface area calculations for the original feeder.
Observation 1: Cleaning validation not performed after equipment replacement. The cleaning validation for Tablet Compression Machine ID # PR034 with feeder ID # PR034 was conducted using a worst-case molecule approach, documented in Cleaning Validation Report VALRP-FS01-000310 (effective October 6, 2020). On March 16, 2024, feeder ID # PR034 underwent breakdown during manufacturing. The firm replaced it with feeder ID # PR182 — a different make and model. The Head of Production stated that the surface area of PR182 was higher than PR034. After multiple requests from investigators, the firm was unable to provide surface area calculations for the original feeder PR034 for verification. As of December 12, 2025, cleaning had not been revalidated for the new equipment train. Under 21 CFR 211.67, equipment and utensils must be cleaned and maintained at appropriate intervals, with written procedures establishing the cleaning methods. When the equipment changes, the validated cleaning procedure may no longer be adequate — particularly when the replacement has a larger surface area, potentially creating new hard-to-clean geometries that the original validation never assessed.
Observation 2: OOS dissolution results invalidated without scientific justification. On April 28, 2025, the firm recorded OOS results for two batches that failed dissolution testing — one at the specified limit against a specification of NLT Q%. In Phase I, the firm confirmed the OOS via re-measurement testing. No root cause was identified. The firm then hypothesised that the OOS “might be the cause of paddle not placed for subjected unit.” Based on this hypothesis, the firm repeated the analysis with fresh sample preparation, obtained passing results, invalidated the original OOS, and released both batches. On December 9, 2025 — during the FDA inspection — an analyst reviewed the Dissolution Analysis Checklist (FORM-FS01-QC-0358) for the implicated batches and confirmed that the paddles had in fact been placed as per the numbering. The stated root cause was contradicted by the firm’s own contemporaneous documentation. Despite this, the original OOS results had already been invalidated and the batches released.
Observation 3: Equipment not requalified after critical component replacement. The Tablet Compression Machine ID # PR034 with feeder ID # PR034 had been qualified per Performance Qualification Report FTS1PRPR034-01 (effective August 8, 2013). After the March 2024 breakdown and replacement of feeder PR034 with PR182 — a different make and model — the firm did not requalify the tablet compression machine assembly. The Head of Production stated that the working principles for the feeders were the same, thus requalification was not needed. Multiple drug products for the US market are manufactured on this equipment train. Under 21 CFR 211.68, control procedures must validate the performance of manufacturing processes that may cause variability in drug product characteristics. A different feeder with different physical dimensions on a tablet compression machine is precisely the kind of change that can introduce variability in weight uniformity, hardness, and content uniformity.
18 months
The firm operated with an unvalidated equipment train for 18 months after replacing the feeder — from March 2024 to December 2025 when the FDA found it
0
The firm could not provide surface area calculations for the original feeder after multiple FDA requests — making it impossible to verify cleaning validation adequacy
3
Three distinct observations — cleaning validation, OOS investigation, and process validation — all traceable to a single uncontrolled equipment change
Three structural failures created the conditions for every observation documented at this facility. Each one represents a point where a system designed to catch equipment changes failed to enforce its own requirements.
When feeder PR034 was replaced with PR182 — a different make and model with a larger surface area — the change should have automatically triggered a cleaning revalidation requirement. It did not, because the equipment change management system and the cleaning validation lifecycle were not connected. The maintenance team replaced the equipment. The production team continued manufacturing. The cleaning validation team was never notified that the equipment train had changed. This is a systems integration failure: when equipment change records do not automatically generate cleaning validation impact assessments, critical changes fall through the gap between departments.
The firm's OOS investigation for the dissolution failures followed a pattern: Phase I confirmed the OOS, no root cause was found, and the investigation hypothesised paddle misplacement. Fresh preparations passed. Original results were invalidated. But the firm's own Dissolution Analysis Checklist — reviewed during the FDA inspection — confirmed that paddles had been placed correctly. The stated root cause was contradicted by contemporaneous documentation that existed in the firm's own quality system. The investigation closed despite this contradiction because there was no architectural requirement to verify the hypothesis against existing records before accepting it as a basis for invalidation.
The performance qualification for the tablet compression machine dated from 2013. When a critical component — the feeder — was replaced with a different make and model twelve years later, the qualified state of the machine was no longer demonstrated. But the equipment qualification system did not flag this because qualification status was tied to the machine ID, not to the specific configuration of components that make up the qualified assembly. The Head of Production's assertion that 'working principles are the same' was accepted as sufficient justification to skip requalification — but different physical dimensions on a tablet compression feeder directly affect powder flow, die fill, and tablet weight uniformity. The system did not require that such assertions be supported by engineering assessments.
The firm’s own Dissolution Analysis Checklist confirmed that paddles were placed correctly — directly contradicting the root cause used to invalidate the OOS results and release the batches. The evidence that disproved the investigation’s conclusion already existed in the quality system. Nobody checked.
Each comparison below addresses a specific gap documented in the Dr. Reddy’s FTO-SEZ 483. The system-enforced approach does not add more manual reviews — it eliminates the structural disconnections that allowed a single equipment change to generate three FDA observations.
A feeder breaks down mid-batch. Maintenance replaces it with a different make and model. The replacement is documented in maintenance records. Production continues. The cleaning validation team is never notified because equipment change records and cleaning validation lifecycles are managed in separate systems. Eighteen months later, the FDA asks for the cleaning validation covering the current equipment train — and it does not exist.
Any equipment component change — replacement, modification, or reconfiguration — automatically generates a cleaning validation impact assessment. The system links equipment asset records to cleaning validation protocols. When a component changes, the system flags affected validation studies, calculates whether the surface area change exceeds the validated range, and blocks the equipment train from production use until the cleaning validation status is resolved. The eighteen-month gap at Dr. Reddy's is structurally impossible because the system will not release equipment for manufacturing without a valid cleaning validation covering the current configuration.
OOS dissolution results are investigated. Phase I confirms the OOS. No root cause found. The investigation hypothesises paddle misplacement. Fresh preparations pass. Original results invalidated. Batches released. The Dissolution Analysis Checklist — which shows paddles were correctly placed — exists in the quality system but is never consulted. The hypothesis contradicts the evidence, but the contradiction is discovered only when the FDA reviews the records during inspection.
When an OOS investigation proposes a root cause, the system requires the investigator to link the conclusion to supporting evidence. For a hypothesis involving equipment setup, the system automatically surfaces the relevant checklist records — dissolution analysis checklists, equipment setup logs, calibration records — and requires the investigator to confirm consistency before the invalidation can proceed. A root cause of 'paddle not placed' cannot be accepted when the paddle placement checklist confirms correct placement. The system enforces evidence consistency, not just evidence collection.
Equipment qualification was performed in 2013. A critical component is replaced with a different make and model in 2024. The qualification status appears unchanged because it is tied to the machine ID (PR034), not to the specific assembly configuration. The Head of Production asserts that 'working principles are the same' and no requalification is performed. Multiple US-market drug products continue to be manufactured on an unqualified equipment configuration.
Equipment qualification records are tied to the specific configuration of the assembly — including component IDs, makes, models, and critical dimensions. When any component in a qualified equipment train is replaced, the qualification status automatically changes to 'pending requalification.' The system requires an engineering impact assessment that evaluates the new component's physical characteristics against the qualified parameters. Assertions that 'working principles are the same' are not accepted without documented engineering data supporting the equivalence claim.
Preventing the Dr. Reddy’s FTO-SEZ pattern requires connecting systems that currently operate in silos — equipment management, cleaning validation, process qualification, and OOS investigation. When these systems are integrated, a single equipment change automatically propagates through every dependent validation and qualification record.
Cleaning validation protocols must be linked to the specific equipment configuration they cover — not just the equipment train ID, but the individual components, their surface areas, and their material of construction. When any component changes, the system automatically identifies affected cleaning validation studies, calculates the impact of surface area changes, and transitions the validation status until the new configuration is assessed and revalidated. At Zydus, CLEEN automated this across 7+ facilities — eliminating manual tracking and ensuring that no equipment train operates outside its validated cleaning state.
OOS investigations must require that proposed root causes are verified against all relevant contemporaneous records before invalidation can proceed. When an investigation proposes an equipment setup root cause, the system must surface the corresponding setup checklists, calibration logs, and operator records — and require the investigator to confirm that the evidence supports the hypothesis. A proposed root cause that is contradicted by existing documentation cannot be accepted. The dissolution paddle example at Dr. Reddy's should have been caught by the system, not by the FDA inspector eighteen months later.
Equipment qualification status must be tied to the specific assembly configuration — including all critical components, their specifications, and their qualified operating parameters. Component replacement triggers automatic requalification assessment. Engineering assertions about equivalence must be documented with dimensional data, material specifications, and functional test results before the system permits the equipment to return to qualified status. At Piramal, Leucine MES tracks equipment configuration across 10+ facilities in 3 regulatory jurisdictions — ensuring that qualification records reflect the actual equipment state, not the state as of the last formal qualification.
80%
Zydus reduced cleaning validation cycle times by 80% through automated HBEL calculations and protocol generation across 7+ facilities — with 100% elimination of manual calculation errors.
10+ facilities
Piramal digitised equipment and manufacturing records across 10+ facilities in 3 regulatory jurisdictions (FDA, MHRA, EMA) — with full 21 CFR Part 11 compliance from day one.
20→1 day
Valent BioSciences reduced batch review from 20 days to 1 day through digitised batch records that connect equipment data, process parameters, and quality records in a single traceable workflow.
The objective is not to add more review steps to equipment change procedures. It is to build an architecture where the disconnections documented at Dr. Reddy’s FTO-SEZ — equipment changes invisible to cleaning validation, OOS conclusions contradicted by existing evidence, qualification status decoupled from actual equipment configuration — are structurally impossible because the system enforces the connections that people and procedures failed to maintain.
Identify every equipment train in the facility. For each one, verify: Is the current cleaning validation study based on the current equipment configuration? Has every component replacement since the last validation been assessed for impact on surface area, material of construction, and cleanability? Is the equipment qualification current against the actual assembly — not the assembly as of the last formal qualification? Review the last 24 months of equipment maintenance records and cross-reference against cleaning validation and qualification records. The Dr. Reddy's 483 tells you exactly what the FDA will ask: show me the cleaning validation for the equipment you are currently using. If the answer requires explaining that a component changed but revalidation was not required, the gap exists.
Deploy integrated equipment lifecycle management where component changes automatically trigger cleaning validation impact assessments and qualification reviews. Configure the system so that equipment trains cannot return to production use after a component change until the cleaning validation and qualification impacts have been assessed and resolved. For OOS investigations, implement evidence-gating that requires proposed root causes to be verified against contemporaneous records before invalidation proceeds. Link dissolution analysis checklists, equipment setup logs, and calibration records to the investigation workflow so that contradictory evidence is surfaced automatically, not discovered during an FDA inspection.
Run challenge scenarios that mirror each observation from the Dr. Reddy's FTO-SEZ 483. Replace a component in an equipment train — verify the system blocks the train from production use and generates cleaning validation and qualification impact assessments. Process an OOS investigation with a proposed root cause that contradicts a contemporaneous checklist — verify the system surfaces the contradiction and prevents invalidation. Attempt to release a batch manufactured on equipment whose qualification does not cover the current configuration — verify the system blocks release. Document all validation evidence under 21 CFR Part 11. When the FDA returns, the system should demonstrate that every gap they found has been closed by architecture, not by additional SOPs.
Dr. Reddy’s replaced a tablet compression feeder with a different make and model in March 2024. For eighteen months, multiple US-market drug products were manufactured on an equipment train with no valid cleaning validation and no current equipment qualification. The firm’s own Head of Production could not provide surface area calculations for the original feeder. Three observations, one root cause: an equipment change control system that exists in procedure but not in architecture.
The Dr. Reddy’s FTO-SEZ 483 is unusual in its traceability. Three observations — cleaning validation, OOS investigation, process validation — all trace back to a single event on a single date: a tablet compression machine feeder that broke down on March 16, 2024. The firm’s response to that breakdown reveals the structural gaps in the quality system with uncomfortable clarity.
The equipment change was not hidden. The maintenance team documented the replacement. The production team knew. The Head of Production was aware that the new feeder had a larger surface area. But the cleaning validation team was never triggered. The equipment qualification team was never triggered. For eighteen months, the facility manufactured multiple US-market drug products on an equipment train whose validated and qualified state no longer reflected reality.
The OOS dissolution finding compounds the concern. When an investigation proposes paddle misplacement as the root cause, and the firm’s own contemporaneous checklist confirms that paddles were correctly placed, the investigation has contradicted itself. The fact that this contradiction was discovered not by the firm’s quality system but by the FDA inspector during the December 2025 inspection demonstrates that the investigation closure process does not verify its own conclusions against existing evidence.
For quality leaders at pharmaceutical manufacturers — particularly those operating multi-product finished dosage facilities with shared equipment — the Dr. Reddy’s FTO-SEZ 483 poses a direct question: when a component in an equipment train is replaced, does your system automatically trigger cleaning revalidation and equipment requalification? Or does it rely on someone in maintenance notifying someone in validation, who then notifies someone in qualification? If the answer involves manual notification between departments, the gap exists. The only question is whether you find it first or the FDA does.
Closing that gap is an architecture problem, not a procedure one: equipment change control has to connect to the cleaning validation and qualification lifecycle in a single system. That is what CLEEN does — and how Zydus automated cleaning validation across 7+ facilities.